Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Assets (2016 - 2026)

Integra Lifesciences Holdings' Assets history spans 17 years, with the latest figure at $3.6 billion for Q4 2025.

  • On a quarterly basis, Assets fell 10.78% to $3.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 billion, a 10.78% decrease, with the full-year FY2025 number at $3.6 billion, down 10.78% from a year prior.
  • Assets hit $3.6 billion in Q4 2025 for Integra Lifesciences Holdings, down from $3.6 billion in the prior quarter.
  • Over the last five years, Assets for IART hit a ceiling of $4.1 billion in Q1 2024 and a floor of $3.6 billion in Q4 2025.
  • Historically, Assets has averaged $3.8 billion across 5 years, with a median of $3.8 billion in 2021.
  • Biggest five-year swings in Assets: grew 9.46% in 2021 and later fell 10.78% in 2025.
  • Tracing IART's Assets over 5 years: stood at $3.8 billion in 2021, then rose by 2.84% to $3.9 billion in 2022, then fell by 2.77% to $3.8 billion in 2023, then grew by 6.75% to $4.0 billion in 2024, then fell by 10.78% to $3.6 billion in 2025.
  • Business Quant data shows Assets for IART at $3.6 billion in Q4 2025, $3.6 billion in Q3 2025, and $3.7 billion in Q2 2025.